(Q37380452)

English

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

scientific article published on 29 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

K L Blackwell

1

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

M D Pegram

2

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

E Tan-Chiu

3

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

L S Schwartzberg

4

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

M C Arbushites

5

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

J D Maltzman

6

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

J K Forster

7

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

S D Rubin

8

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

S H Stein

9

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

H J Burstein

10

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

publication date

29 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1026-1031

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Epidermal growth factor receptor: mechanisms of activation and signalling.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Brain metastases: the HER2 paradigm

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Lapatinib: current status and future directions in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Concurrent chemoradiation for locally advanced carcinoma of the cervix: where are we in 2006?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN759

21 January 2018

Identifiers

10.1093/ANNONC/MDN759

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37380452&oldid=1703104159"